Coursera Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Coursera Inc trades at $5.55 (market cap $1.50B), while State Street SPDR S&P Biotech ETF trades at $159.8. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| COUR | XBI | |
|---|---|---|
Market Cap | $1.50B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $12.20 | $164.28 |
52-Week Low | $5.09 | $86.92 |
Enterprise Value | $759.54M | — |
Signals from Pluang's Aura AI — not financial advice
COUR trades at $5.76, down 0.86% today, with a neutral technical signal. Revenue grew to $757.5M in 2025, but net income remains negative at -$51M. The company recently beat Q2 2026 EPS estimates at $0.17 versus $0.10 expected. Positive cash flow from operations of $108.7M in 2025 supports liquidity, while a $100M investment in LearnVector highlights strategic AI focus.
Outlook is mixed: analyst consensus is bullish with a $7.70 price target (34% upside), but persistent losses and competitive pressures pose risks. The stock offers growth potential if profitability improves, yet high SG&A costs and integration challenges from the Udemy acquisition require monitoring.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Trailing returns across standard periods
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →